Supernus Pharmaceuticals reported $-21.04M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
Abbott USD 1.36B 775M Sep/2026
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Aurora Cannabis CAD -3.17M 10.29M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -2.03M 143.62M Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Eisai JPY 16.7B 8.03B Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Perrigo USD 27.2M 116.6M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Xeris Pharmaceuticals USD -24.15M 33.27M Jun/2026